These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 20929320)

  • 1. Complete remission following treatment with bortezomib, doxorubicin, dexamethasone and autologous stem cell transplant in patient with immunoglobulin E multiple myeloma.
    Pogłód R; Kraj M; Kruk B; Hagedorna-Tronina R; Łetowska M; Warzocha K
    Leuk Lymphoma; 2010 Dec; 51(12):2291-4. PubMed ID: 20929320
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients.
    Silvennoinen R; Kairisto V; Pelliniemi TT; Putkonen M; Anttila P; Säily M; Sikiö A; Opas J; Penttilä K; Kuittinen T; Honkanen T; Lundán T; Juvonen V; Luukkaala T; Remes K
    Br J Haematol; 2013 Feb; 160(4):561-4. PubMed ID: 23206270
    [No Abstract]   [Full Text] [Related]  

  • 3. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
    Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
    Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Partial recovery of kidney function for an autologous transplant in a patient with chronic kidney disease and multiple myeloma].
    de Alarcón Jiménez RM; Roca Meroño S; Alvarez Fernández GM; García Hernández MA; Navarro Parreño MJ; Jimeno Griñó C; Zarco Pedrinaci E; Molina Núñez M
    Nefrologia; 2011; 31(2):238-40. PubMed ID: 21461027
    [No Abstract]   [Full Text] [Related]  

  • 6. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.
    Leleu X; Fouquet G; Hebraud B; Roussel M; Caillot D; Chrétien ML; Arnulf B; Szalat R; Garderet L; Benajiba L; Pegourie B; Regny C; Royer B; Caulier A; Stoppa AM; Garciaz S; Touzeau C; Chaleteix C; Fermand JP; Loiseau HA; Facon T; Attal M; Moreau P;
    Leukemia; 2013 Nov; 27(11):2242-4. PubMed ID: 23558525
    [No Abstract]   [Full Text] [Related]  

  • 7. Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma.
    Corso A; Barbarano L; Mangiacavalli S; Spriano M; Alessandrino EP; Cafro AM; Pascutto C; Varettoni M; Bernasconi P; Grillo G; Carella AM; Montalbetti L; Lazzarino M; Morra E
    Leuk Lymphoma; 2010 Feb; 51(2):236-42. PubMed ID: 20001242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
    Wang M; Giralt S; Delasalle K; Handy B; Alexanian R
    Hematology; 2007 Jun; 12(3):235-9. PubMed ID: 17558699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma].
    Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gal'tseva IV; Kuz'mina LA; Akhundova FM; Kalinin NN; Gretsov EM; Parovichnikova EN; Savchenko VG
    Ter Arkh; 2012; 84(7):35-41. PubMed ID: 23038970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
    Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
    Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
    Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
    J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma.
    Lok A; Mocquard J; Bourcier J; Redelsperger L; Bonnet A; Chauvin C; Thomaré P; Mahé B; Touzeau C; Moreau P
    Haematologica; 2014 Mar; 99(3):e33-4. PubMed ID: 24532044
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.
    Benson DM; Panzner K; Hamadani M; Hofmeister CC; Bakan CE; Smith MK; Elder P; Krugh D; O'Donnell L; Devine SM
    Leuk Lymphoma; 2010 Feb; 51(2):243-51. PubMed ID: 20038230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete remission of psoriasis after autologous hematopoietic stem-cell transplantation for multiple myeloma.
    Braiteh F; Hymes SR; Giralt SA; Jones R
    J Clin Oncol; 2008 Sep; 26(27):4511-3. PubMed ID: 18802165
    [No Abstract]   [Full Text] [Related]  

  • 15. Induction therapy for newly diagnosed multiple myeloma.
    Lonial S; Miguel JF
    J Natl Compr Canc Netw; 2013 Jan; 11(1):19-28. PubMed ID: 23307978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.
    Sekiguchi Y; Shimada A; Wakabayashi M; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
    Int J Clin Exp Pathol; 2014; 7(9):6313-22. PubMed ID: 25337285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hematopoietic stem cell transplantation for multiple myeloma].
    Kanda Y
    Rinsho Ketsueki; 2009 Oct; 50(10):1420-6. PubMed ID: 19915350
    [No Abstract]   [Full Text] [Related]  

  • 18. Bortezomib in combination with thalidomide and dexamethasone--a successful treatment regimen in refractory extramedullary multiple myeloma.
    Dytfeld D; Matuszak M; Lewandowski K; Komarnicki M
    Ann Hematol; 2008 Mar; 87(3):253-4. PubMed ID: 17955241
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of transplant-eligible symptomatic multiple myeloma].
    Nakaseko C
    Rinsho Ketsueki; 2014 Oct; 55(10):2016-26. PubMed ID: 25297767
    [No Abstract]   [Full Text] [Related]  

  • 20. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
    Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.